Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Change in Acquisitions & Divestments (2020 - 2025)

Lyell Immunopharma's Change in Acquisitions & Divestments history spans 6 years, with the latest figure at $74.1 million for Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments fell 44.43% year-over-year to $74.1 million; the TTM value through Sep 2025 reached $445.5 million, down 23.37%, while the annual FY2024 figure was $548.9 million, 17.28% down from the prior year.
  • Change in Acquisitions & Divestments for Q3 2025 was $74.1 million at Lyell Immunopharma, down from $93.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $204.2 million in Q1 2021 and bottomed at $70.3 million in Q4 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $133.4 million (2024), against an average of $135.3 million.
  • The largest annual shift saw Change in Acquisitions & Divestments crashed 65.81% in 2021 before it soared 78.24% in 2023.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $70.3 million in 2021, then surged by 57.68% to $110.9 million in 2022, then skyrocketed by 40.78% to $156.1 million in 2023, then dropped by 20.77% to $123.7 million in 2024, then tumbled by 40.07% to $74.1 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Change in Acquisitions & Divestments are $74.1 million (Q3 2025), $93.5 million (Q2 2025), and $154.1 million (Q1 2025).